PACIFIC DIAGNOSTIC LABORATORIES

PDC (Outreach Lab Only)

Antimicrobial Susceptibility Profile January – December 2018

Percent Susceptible[1]

ORGANISM[1]	AVG. SAMPLE SIZE	AMPICILLIN	AMP / SUL	NAFCIL / OXACIL	PIP / TAZO	TETRACYCLINE	CEFAZOLIN	CEFTRIAXONE	CEFTAZIDIME	CEFEPIME	CIPROFLOXACIN	LEVOFLOXACIN	GENTAMICIN	IMIPENEM	ERTAPENEM	TRIMETH / SULFA	NITROFURAN (3)	CLINDAMYCIN	ERYTHROMYCIN	VANCOMYCIN	LINEZOLID	RIFAMPIN (4)	MEROPENEM
***Escherichia coli* (all)**	9401	58	64		97		88	93	93	99	84	84	91	100	100	75	96						100
***Escherichia coli* ESBL[7] (all)**	564	0	0		91		0	0	0	83	27	27	62	99	100	46	86						100
***Escherichia coli* (Urines)**	8501	62	68		97		94	99	99	100	87	88	93	100	100	77	96						
***Escherichia coli* ESBL[7] (Urines)**	528	0	0		91		0	0	0	84	27	27	63	100	100	46	85						100
Klebsiella pneumoniae	1494		85		96		93	94	94	99	96	97	97	100	100	89	29						100
Klebsiella oxytoca	242		67		97		74	99	100	100	100	100	99	99	100	95	78						100
***Klebsiella sp.* ESBL[7]**	89		0		71		0	0	0	79	54	74	56	99	99	24	16						100
Pseudomonas aeruginosa	747				90				94		90	86	95	94									83
Enterobacter aerogenes	168				86			86	86	100	100	100	100	61	99	100	10						100
***Enterobacter cloacae* complex**	289				83			81	83	96	99	99	100	90	99	92	26						100
Proteus mirabilis	699	85	93		100		95	98	99	100	89	92	96	11	100	85							100
***Citrobacter freundii* complex**	132							79	80	99	91	91	91	95	100	80	95						100
Citrobacter koseri (diversus)	193				99		98	98	99	100	99	99	100	99	100	99	87						100
Serratia marcescens	127				96			98	99	99	98	98	98	75	99	99							100
Haemophilus influenza	1	100						100			100												100

Staphylococcus aureus	3759			71		91	(2)				67	69	97			96	100	78	52	100	100	99	
***Staphylococcus aureus* (MSSA)**	2665			100		91	(2)				87	88	98			98	100	81	69	100	100	100	
***Staphylococcus aureus* (MRSA)**	1094			0		84	(2)				20	21	94			93	100	72	11	100	100	99	
***Enterococcus* spp.**	1390	98									85	86[5]					95			98	98		
Enterococcus faecalis	257	99									84	84[5]					99			97	96		
***Enterococcus faecalis* (VRE)**	7	100									0	0					100			0	50		
Enterococcus faecium	42	76									35	31[5]					32			83	94		
***Enterococcus faecium* (VRE)**	17	0									0	0					6			0	100		
Coagulase Negative Staph.	334			51		84	(2)				71	72[6]				77	99	75	48	99	100		
Streptococcus pneumoniae	101			100								100				76		88	73	100			

Footnotes:

1. **Profiles include data from disk diffusion, automated testing and gradient diffusion MIC. Intermediate results have been interpreted as resistant for this tabulation. All isolates were not tested against each antibiotic in the profile.**

2. **Refer to oxacillin results. Oxacillin resistant strains may not respond to beta lactam antibiotics such as penicillins, cephalosporins, and imipenem.**

3. **Data apply only to organisms isolated from urinary tract.**

4. **Rifampin should not be used as a sole agent for antimicrobial therapy.**

5. **Fluoroquinolones are generally not an appropriate therapy against enterococcus infections from sites other than urine.**

6. **Staphylococcus isolates may become resistant to fluoroquinolones within 3-4 days after initiation of therapy. (CLSI M100-Ed 28, 2018)**

7. **ESBL rate is 6.0% for *E. coli* and 4.9% for all *Klebsiella* sp.**

PACIFIC DIAGNOSTIC LABORATORIES
SANTA BARBARA, CA

ANTIBIOTIC SUSCEPTIBILITY PROFILES
2018

PDL Out Patients only

DEPARTMENT OF MICROBIOLOGY

DR. STEWART COMER,
MEDICAL DIRECTOR
SCOMER@SBCH.ORG
(805) 569-7367

JANE CHOE,
MICROBIOLOGY MANAGER
JCHOE@SBCH.ORG
(805) 324-9813